Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.75
-0.14 (-2.38%)
Nov 20, 2024, 4:00 PM EST - Market closed
Abeona Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | - | 3.5 | 1.41 | 3 | 10 | - | Upgrade
|
| Revenue Growth (YoY) | - | 147.52% | -52.87% | -70.00% | - | - | Upgrade
|
| Cost of Revenue | 23.54 | 32.7 | 29.42 | 38.73 | 30.14 | 48.57 | Upgrade
|
| Gross Profit | -23.54 | -29.2 | -28 | -35.73 | -20.14 | -48.57 | Upgrade
|
| Selling, General & Admin | 28 | 19 | 17.26 | 21.64 | 23.78 | 20.71 | Upgrade
|
| Research & Development | 9.21 | - | - | - | - | - | Upgrade
|
| Operating Expenses | 37.21 | 19 | 17.26 | 21.64 | 28.37 | 28.52 | Upgrade
|
| Operating Income | -60.75 | -48.2 | -45.26 | -57.37 | -48.5 | -77.09 | Upgrade
|
| Interest Expense | -3.24 | -0.42 | -0.74 | -3.66 | -4.12 | -0.4 | Upgrade
|
| Interest & Investment Income | 3.97 | 2.12 | 0.43 | 0.04 | 1.3 | 1.21 | Upgrade
|
| Other Non Operating Income (Expenses) | -10.97 | -8.71 | 11.66 | 0.02 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -70.99 | -55.21 | -33.9 | -60.97 | -51.32 | -76.28 | Upgrade
|
| Impairment of Goodwill | - | - | - | -32.47 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.05 | -0.05 | -0.14 | - | - | - | Upgrade
|
| Asset Writedown | - | 1.07 | -5.66 | - | -32.92 | - | Upgrade
|
| Other Unusual Items | - | - | - | 8.5 | - | - | Upgrade
|
| Pretax Income | -71.03 | -54.19 | -39.7 | -84.94 | -84.23 | -76.28 | Upgrade
|
| Net Income | -71.03 | -54.19 | -39.7 | -84.94 | -84.23 | -76.28 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | 3.78 | - | - | - | Upgrade
|
| Net Income to Common | -71.03 | -54.19 | -43.48 | -84.94 | -84.23 | -76.28 | Upgrade
|
| Shares Outstanding (Basic) | 35 | 21 | 8 | 4 | 4 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 35 | 21 | 8 | 4 | 4 | 2 | Upgrade
|
| Shares Change (YoY) | 93.20% | 171.96% | 99.65% | 6.24% | 84.02% | 5.95% | Upgrade
|
| EPS (Basic) | -2.01 | -2.53 | -5.53 | -21.57 | -22.73 | -37.87 | Upgrade
|
| EPS (Diluted) | -2.01 | -2.53 | -5.53 | -21.57 | -22.73 | -37.87 | Upgrade
|
| Free Cash Flow | -50.57 | -37.34 | -43.61 | -69.82 | -36.36 | -69.13 | Upgrade
|
| Free Cash Flow Per Share | -1.43 | -1.75 | -5.55 | -17.73 | -9.81 | -34.32 | Upgrade
|
| Gross Margin | - | - | - | - | -201.39% | - | Upgrade
|
| Operating Margin | - | -1377.14% | -3200.64% | -1912.33% | -485.04% | - | Upgrade
|
| Profit Margin | - | -1548.23% | -3074.82% | -2831.20% | -842.34% | - | Upgrade
|
| Free Cash Flow Margin | - | -1066.86% | -3084.37% | -2327.20% | -363.55% | - | Upgrade
|
| EBITDA | -58.79 | -45.91 | -42.16 | -54.12 | -43.92 | -69.27 | Upgrade
|
| D&A For EBITDA | 1.96 | 2.29 | 3.09 | 3.25 | 4.59 | 7.82 | Upgrade
|
| EBIT | -60.75 | -48.2 | -45.26 | -57.37 | -48.5 | -77.09 | Upgrade
|
| Revenue as Reported | - | - | - | - | 10 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.